Nonalcoholic fatty liver disease: What do we know and what will we have to learn?


Cite item

Full Text

Abstract

The article reviews relevant data on the prevalence, natural history, pathogenesis, diagnosis, and treatment of nonalcoholic fatty liver disease and critically assesses the fixed notion of this disease.

About the authors

N I Volkova

Ростовский государственный медицинский университет Минздрава России

Ростов-на-Дону, Россия

M I Porksheyan

Ростовский государственный медицинский университет Минздрава России

Ростов-на-Дону, Россия

References

  1. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124. doi: 10.1053/j.gastro.2010.09.038
  2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol Ther. 2011;4:274. doi: 10.1111/j.1365-2036.2011.04724.x
  3. Lazo M, Hernaez R, Eberhardt MS et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013;178:38. doi: 10.1093/aje/kws448
  4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434. doi: 10.1016/s0025-6196(11)64621-1
  5. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20:594. doi: 10.1016/0046-8177(89)90249-9
  6. Powell EE, Cooksley WG, Hanson R et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74. doi: 10.1016/j.jhep.2004.02.013
  7. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology. 1988;95:1056. doi: 10.1111/j.1572-0241.2000.02748.x
  8. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103. doi: 10.1016/0270-9139(95)90482-4
  9. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917. doi: 10.1053/jhep.2003.50161
  10. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106. doi: 10.1002/hep.1840120505
  11. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450. doi: 10.1016/s0002-9343(99)00271-5
  12. Cello JP, Grendell JH. The liver in systemic conditions. In: Hepatology. Zakim D, Boyer TD, eds. Philadelphia: WB Saunders; 1990:1428. doi: 10.1016/0270-9139(91)90240-v
  13. Pinto HC, Baptista A, Camilo ME et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 1996;41:172. doi: 10.1007/bf02208601
  14. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol. 1987;82:650. doi: 10.1111/j.1530-0277.2008.00755.x
  15. Fracanzani AL, Valenti L, Bugianesi E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792. doi: 10.1002/hep.22429
  16. Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton, Arun J. Sanyal. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association or the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. doi: 10.1038/ajg.2012.128
  17. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342. doi: 10.1016/j.cgh.2012.10.001
  18. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371. doi: 10.1016/j.jhep.2009.03.019
  19. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356. doi: 10.1002/hep.510300604
  20. Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117. doi: 10.1016/s0016-5085(00)70364-7
  21. Noureddin M, Yates KP, Vaughn IA et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58:1644. doi: 10.1002/hep.26465
  22. Hossain N, Afendy A, Stepanova M et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1224. doi: 10.1016/j.cgh.2009.06.007
  23. Francque SM, Verrijken A, Mertens I et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol. 2012;10:1162. doi: 10.1016/j.cgh.2012.06.019
  24. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413. doi: 10.1016/s0016-5085(99)70506-8
  25. Petta S, Amato MC, Di Marco V et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:238. doi: 10.1111/j.1365-2036.2011.04929.x
  26. Molloy JW, Calcagno CJ, Williams CD et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429. doi: 10.1002/hep.24731
  27. Lazo M, Hernaez R, Bonekamp S et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:d6891. doi: 10.1136/bmj.d6891
  28. Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865. doi: 10.1002/hep.21327
  29. Rafiq N, Bai C, Fang Y et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234. doi: 10.1016/j.cgh.2008.11.005
  30. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49:608. doi: 10.1016/j.jhep.2008.06.018
  31. Söderberg C, Stål P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595. doi: 10.1002/hep.23314
  32. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10:646. doi: 10.1016/j.cgh.2011.12.039
  33. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103. doi: 10.1016/0270-9139(95)90482-4
  34. Fracanzani AL, Valenti L, Bugianesi E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792. doi: 10.1002/hep.22429
  35. Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286. doi: 10.1053/jhep.2003.50229
  36. Диагностика и лечение неалкогольной жировой болезни печени. Методические рекомендации для врачей. Под ред. Ивашкина В.Т. 2015.
  37. Kowdley KV, Belt P, Wilson LA et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:77. doi: 10.1002/hep.24706
  38. Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, Robson S, Afdhal N, Lai M. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci. 2015 Oct 13. doi: 10.1007/s10620-015-3916-1
  39. Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082. doi: 10.1002/hep.24452
  40. Rofsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound. CT MR 1995;16:16. doi: 10.1016/0887-2171(95)90012-8
  41. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci. 1993;38:1480. doi: 10.1007/bf01308607
  42. Dunn W, Angulo P, Sanderson S et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology. 2006;131:1057. doi: 10.1053/j.gastro.2006.08.020
  43. Food Drug Administration. Accessed July 29, 2015. Available et: http://www.accessdata.fda.gov/cdrh_docs/pdf12/K123806.pdf
  44. Koplay M, Sivri M, Erdogan H, Nayman A. Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease. World J Hepatol. 2015;7(5):769-776. doi: 10.4254/wjh.v7.i5.769
  45. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. 2006;44:462. doi: 10.1016/j.jhep.2005.10.019
  46. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313. doi: 10.1002/hep.20701
  47. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991;12:224. doi: 10.1016/0168-8278(91)90942-5
  48. Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916. doi: 10.12968/bjca.2011.6.2.94a
  49. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2010; 32:1211. doi: 10.1111/j.1365-2036.2010.04467.x
  50. Merat S, Malekzadeh R, Sohrabi MR et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol. 2003;38:414. doi: 10.1016/s0168-8278(02)00441-5
  51. Zelber-Sagi S, Kessler A, Brazowsky E et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4:639. doi: 10.1016/j.cgh.2006.02.004
  52. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology. 2009;49:80. doi: 10.1002/hep.22575
  53. Abdelmalek MF, Sanderson SO, Angulo P et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology. 2009;50:1818. doi: 10.1002/hep.23239
  54. Dufour JF, Oneta CM, Gonvers JJ et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4:1537. doi: 10.1016/j.cgh.2006.09.025
  55. Pietu F, Guillaud O, Walter T et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clin Res Hepatol Gastroenterol. 2012;36:146. doi: 10.1016/j.clinre.2011.10.011
  56. Leuschner UF, Lindenthal B, Herrmann G et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010; 52:472. doi: 10.1002/hep.23727
  57. Foster T, Budoff MJ, Saab S et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106:71. doi: 10.1038/ajg.2010.299
  58. Zein CO, Yerian LM, Gogate P et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54:1610. doi: 10.1002/hep.24544
  59. Parker HM, Johnson NA, Burdon CA et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;56:944. doi: 10.1016/j.jhep.2011.08.018
  60. Safadi R, Konikoff FM, Mahamid M et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085. doi: 10.1016/j.cgh.2014.04.038
  61. Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956. doi: 10.1016/s0140-6736(14)61933-4
  62. Mavin Macauley, Kieren G. Hollingsworth, Fiona E. Smith, Peter E. Thelwall, Ahmad Al-Mrabeh, Anja Schweizer, James E. Foley, Roy Taylor. Effect of Vildagliptin on Hepatic Steatosis. Jcem.endojournals.org. J Clin Endocrinol Metab. 2015;100(4): 1578-1585. doi: 10.1210/jc.2014-3794

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies